Ocular Therapeutix, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OCUL research report →
Companywww.ocutx.com
Ocular Therapeutix, Inc. , a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
- CEO
- Pravin U. Dugel
- IPO
- 2014
- Employees
- 274
- HQ
- Bedford, MA, US
Price Chart
Valuation
- Market Cap
- $1.76B
- P/E
- -6.19
- P/S
- 33.79
- P/B
- 3.09
- EV/EBITDA
- -4.16
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 87.24%
- Op Margin
- -575.42%
- Net Margin
- -558.24%
- ROE
- -64.55%
- ROIC
- -43.52%
Growth & Income
- Revenue
- $51.82M · -18.67%
- Net Income
- $-265,939,000 · -37.43%
- EPS
- $-1.42 · -16.39%
- Op Income
- $-270,017,000
- FCF YoY
- -59.52%
Performance & Tape
- 52W High
- $16.44
- 52W Low
- $6.23
- 50D MA
- $8.92
- 200D MA
- $10.90
- Beta
- 0.93
- Avg Volume
- 4.10M
Get TickerSpark's AI analysis on OCUL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 9, 26 | Dugel Pravin | other | 394,696 |
| Apr 9, 26 | Dugel Pravin | other | 394,696 |
| Feb 23, 26 | Dugel Pravin | sell | 20,056 |
| Feb 23, 26 | Kaiser Peter | sell | 2,810 |
| Feb 23, 26 | Heier Jeffrey S. | sell | 3,057 |
| Feb 23, 26 | Nayak Sanjay | sell | 1,759 |
| Feb 20, 26 | Waheed Nadia | sell | 3,510 |
| Feb 20, 26 | LINDSTROM RICHARD L MD | buy | 60,229 |
| Feb 12, 26 | Notman Donald | sell | 11,446 |
| Feb 12, 26 | Nayak Sanjay | sell | 10,348 |
Our OCUL Coverage
We haven't published any research on OCUL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OCUL Report →